NCT02062684 - BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

March 31, 2017

Study Completion Date

June 30, 2017

Conditions

IgA Nephropathy

Interventions

DRUG

Blisibimod

DRUG

Placebo

Trial Locations (23)

500

Investigator Site 704, Changhua

1101

Investigator Site 402, Quezon City

10330

Investigator Site 504, Bangkok

10400

Investigator Site 505, Bangkok

10700

Investigator Site 503, Bangkok

40210

Investigator Site 905, Düsseldorf

43000

Investigator Site 603, Kajang

50200

Investigator Site 501, Chang Mai

70428

Investigator Site 705, Tainan City

169608

Investigator Site 202, Singapore

308433

Investigator Site 201, Singapore

Unknown

Investigator Site 852, Olomouc

Investigator 851, Prague

Investigator Site 101, Hong Kong

Investigator Site 401, Quezon City

Investigator Site 806, Bradford

Investigator Site 801, Leicester

Investigator Site 803, London

612-896

Investigator Site 305, Busan

614-735

Investigator Site 306, Busan

301-721

Investigator Site 303, Daejeon

110-744

Investigator Site 301, Seoul

137-701

Investigator Site 302, Seoul